Astellas, Pfizer agree to co-promote Caduet

More co-promotion for Astellas Pharma. The Japanese company inked a deal with Pfizer to promote the latter's combo cardiovascular drug Caduet. Pfizer will make and sell the drug, which puts the blood-pressure treatment Norvasc and cholesterol drug Lipitor in one tablet. Astellas and Pfizer will promote the drug together; Pfizer will book sales and Astellas will get a fee.

Earlier this month, Astellas made a deal with AstraZeneca to co-promote the asthma drug Symbicort. AstraZeneca is already looking for government approval of the drug in Japan; once it's OK'd for the market, Astellas will handle sales through its already established channels, and the two companies will both promote the product. 

- see the Astellas release

Related Articles:
Astellas reorganizes R&D ops
Astellas drops bid for CV Therapeutics

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.